Cyclophosphamide - Accentia Biopharmaceuticals/Biovest International

Drug Profile

Cyclophosphamide - Accentia Biopharmaceuticals/Biovest International

Alternative Names: Cyrevia; HiCy

Latest Information Update: 11 Sep 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Accentia Biopharmaceuticals; Biovest International
  • Class Antineoplastics; Antirheumatics; Cyclophosphamides; Myeloablative agonists; Small molecules
  • Mechanism of Action Alkylating agents; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Autoimmune haemolytic anaemia; Systemic scleroderma

Highest Development Phases

  • Discontinued Multiple sclerosis; Transplant rejection

Most Recent Events

  • 11 Sep 2013 Discontinued - Preclinical for Multiple sclerosis in USA (IV)
  • 11 Sep 2013 Discontinued - Preclinical for Transplant rejection in USA (IV)
  • 14 Sep 2011 Cyrevia™ receives Orphan Drug status for Graft-versus-host disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top